Kymera Investor Presentation Deck

KYMERA KYMERA ● ● Dosed first patient in KT-474 Hidradenitis Suppurativa Phase 2 clinical trial Initial patient dose generated first development milestone ($40M) from Sanofi Demonstrated initial KT-333 anti-tumor activity in Phase 1 clinical trial; additional disclosure expected in poster at ASH 2023 ● Recent Accomplishments Demonstrated proof-of-mechanism in KT-253 and initial antitumor activity in first patient cohort without typical MDM2 hematologic toxicity Reprioritized pipeline, allocating resources and capital to emerging immunology pipeline Extended cash runway into first half of 2026 ©2023 KYMERA THERAPEUTICS, INC. PAGE 4

View entire presentation